Search Results for "Sk Biopharmaceuticals Korea"

10:49 EST 20th December 2014 | BioPortfolio

Original Source: SK Biopharmaceuticals

SK Biopharmaceuticals, a research and development company specializing in the discovery of small molecule drug candidates and their development from drug target through commercialization will remain in their headquarters in Fairfield, New Jersey. SK Energy & Chemicals, which manufactures and develops fine chemicals, pharmaceutical intermediates, and API's, will remain in their Fair Lawn, New Jersey offices. SK USA is the US headquarters for SK Group, Korea's third largest conglomerate. SK USA develops new ...

Matching Channels

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

BioPortfolio Twitter Accounts

BioPortfolio has created approx 150 Twitter accounts with currently (June 2013 - 25,000 Twitter Followers) to support our users interest in keeping upto date on the latest news, research papers, rep...

Matching News

The ICIST-KAIST International Conference 2014 from August 4-8, 2014 in Korea

(The Korea Advanced Institute of Science and Technology (KAIST)) 'Does science lead progress?' This thought-provoking question will be explored this summer, August 4-8, 2014, with hundreds of universi...

BASF Opens Electronics R&D Center in Korea

BASF has opened its new regional Electronic Materials R&D Center in Korea at Sungkyunkwan University's (SKKU) Suwon Campus in Gyeonggi. The new facility, the German group's first R&D base in K...

Purple not yet the new orange: US FDA biopharmaceuticals list lacks dates

A new list of biopharmaceuticals published by the US FDA provides limited information with only the entries for Neupogen, Perjecta and Granix including expiry dates.

Alder BioPharmaceuticals regains pharma licensing rights from BMS

Alder BioPharmaceuticals has regained the worldwide pharma licensing rights to clazakizumab, a humanized monoclonal antibody to the pro-inflammatory cytokine IL-6, from Bristol-Myers Squibb based on B...

DPx Holdings Acquires Gallus BioPharmaceuticals

DPx Holdings reaches definitive agreement to acquire all shares of Gallus biopharmaceuticals.

CPhI Korea 2014 Scheduled for Sept. 2-3

CPhI Korea trade show provides industry leaders access to the growing South Korean market.

BRIEF-ThromboGenics says Jetrea wins approval in South Korea

* Has been approved in South Korea for treatment of adults with symptomatic vitreomacular adhesion (VMA) Further company coverage:

Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announ...

Matching PubMed Articles

Mini-review: Targeted biopharmaceuticals for cancer treatment.

Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. Th...

Biopharmaceutical discovery and production in yeast.

The selection of an expression platform for recombinant biopharmaceuticals is often centered upon suitable product titers and critical quality attributes, including post-translational modifications. A...

Cost-of-Illness Trend of Thyroid Gland Disease in Korea.

Contributions to the foliicolous lichens flora of South Korea.

South Korea is covered primarily by temperate vegetation; therefore, foliicolous lichens may not be expected to play an important role in its lichen flora. However, this study describes four foliicolo...

Cost-of-Illness Trends Associated with Thyroid Disease in Korea.

The purpose of this study is to analyze the scale of and trends associated with the cost-of-illness of thyroid disease in Korea at 2-year intervals during the last 10 years for which data are availabl...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement